Despite effective antiretroviral therapy, HIV-1–infected cells continue to produce viral antigens and induce chronic immune exhaustion. We propose to identify HIV-1–suppressing agents that can inhibit HIV-1 reactivation and reduce HIV-1–induced immune activation. Using a newly developed dual-reporter system and a high-throughput drug screen, we identified FDA-approved drugs that can suppress HIV-1 reactivation in both cell line models and CD4+ T cells from virally suppressed HIV-1–infected individuals. We identified 11 cellular pathways required for HIV-1 reactivation as druggable targets. Using differential expression analysis, gene set enrichment analysis, and exon-intron landscape analysis, we examined the impact of drug treatment on the cellular environment at a genome-wide level. We identified what we believe to be a new function of a JAK inhibitor, filgotinib, that suppresses HIV-1 splicing. First, filgotinib preferentially suppresses spliced HIV-1 RNA transcription. Second, filgotinib suppresses HIV-1–driven aberrant cancer-related gene expression at the integration site. Third, we found that filgotinib suppresses HIV-1 transcription by inhibiting T cell activation and by modulating RNA splicing. Finally, we found that filgotinib treatment reduces the proliferation of HIV-1–infected cells. Overall, the combination of a drug screen and transcriptome analysis provides systematic understanding of cellular targets required for HIV-1 reactivation and drug candidates that may reduce HIV-1–related immune activation.
Yang-Hui Jimmy Yeh, Katharine M. Jenike, Rachela M. Calvi, Jennifer Chiarella, Rebecca Hoh, Steven G. Deeks, Ya-Chi Ho
Title and authors | Publication | Year |
---|---|---|
Machine Learning Bolsters Evidence That D1, Nef, and Tat Influence HIV Reservoir Dynamics
Cannon L, Fehrman S, Pinzone M, Weissman S, O'Doherty U |
Pathogens and Immunity | 2024 |
Immunosuppressants exert antiviral effects against influenza A(H1N1)pdm09 virus via inhibition of nucleic acid synthesis, mRNA splicing, and protein stability.
Wang X, Pu F, Yang X, Feng X, Zhang J, Duan K, Nian X, Ma Z, Ma XX, Yang XM |
Virulence | 2024 |
Persistent HIV-1 transcription during ART: time to reassess its significance?
Fombellida-Lopez C, Berkhout B, Darcis G, Pasternak AO |
Current Opinion in HIV and AIDS | 2024 |
Targeting Viral Transcription for HIV Cure Strategies.
Izquierdo-Pujol J, Puertas MC, Martinez-Picado J, Morón-López S |
Microorganisms | 2024 |
Transcription of HIV-1 at sites of intact latent provirus integration
Teixeira AR, Bittar C, Silva Santos GS, Oliveira TY, Huang AS, Linden N, Ferreira IA, Murdza T, Muecksch F, Jones RB, Caskey M, Jankovic M, Nussenzweig MC |
2024 | |
Post-Transcriptional HIV-1 Latency: A Promising Target for Therapy?
Kobayashi-Ishihara M, Tsunetsugu-Yokota Y |
Viruses | 2024 |
Effects of an indole derivative on cell proliferation, transfection, and alternative splicing in production of lentiviral vectors by transient co-transfection
Mier NC, Roper DK |
PloS one | 2024 |
Mechanisms and efficacy of small molecule “latency promoting agents” to inhibit HIV reactivation in cells from people with HIV
Julie Janssens, Peggy Kim, Sun Jin Kim, Adam Wedrychowski, Gayatri Kadiyala, Peter Hunt, Steven Deeks, Joseph Wong, Steven Yukl |
JCI Insight | 2024 |
Transcription of HIV-1 at sites of intact latent provirus integration.
Teixeira AR, Bittar C, Silva Santos GS, Oliveira TY, Huang AS, Linden N, Ferreira IATM, Murdza T, Muecksch F, Jones RB, Caskey M, Jankovic M, Nussenzweig MC |
The Journal of experimental medicine | 2024 |
Silencing the transcriptionally active HIV reservoir to improve treatment outcomes.
Prigann J, Tavora R, Furler O'Brien RL, Schulze-Gahmen U, Boehm D, Roan NR, Nixon DF, Ndhlovu LC, Valente S, Ott M |
Nature microbiology | 2024 |
Exploiting the Achilles’ Heel of Viral RNA Processing to Develop Novel Antivirals
Zahedi Amiri A, Ahmed C, Dahal S, Grosso F, Leng H, Stoilov P, Mangos M, Toutant J, Shkreta L, Attisano L, Chabot B, Brown M, Huesca M, Cochrane A |
Viruses | 2024 |
Integration site–dependent HIV-1 promoter activity shapes host chromatin conformation
Collora JA, Ho YC |
Genome research | 2023 |
Single-cell epigenetic, transcriptional, and protein profiling of latent and active HIV-1 reservoir revealed that IKZF3 promotes HIV-1 persistence
Wei Y, Davenport TC, Collora JA, Ma HK, Pinto-Santini D, Lama J, Alfaro R, Duerr AC, Ho YC |
Immunity | 2023 |
DEAD-ly Affairs: The Roles of DEAD-Box Proteins on HIV-1 Viral RNA Metabolism
Rao S, Mahmoudi T |
Frontiers in Cell and Developmental Biology | 2022 |
Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T cell clones
Collora JA, Liu R, Pinto-Santini D, Ravindra N, Ganoza C, Lama JR, Alfaro R, Chiarella J, Spudich S, Mounzer K, Tebas P, Montaner LJ, van Dijk D, Duerr A, Ho YC |
Immunity | 2022 |
Inhibition of a Chromatin and Transcription Modulator, SLTM, Increases HIV-1 Reactivation Identified by a CRISPR Inhibition Screen.
Pedersen SF, Collora JA, Kim RN, Yang K, Razmi A, Catalano AA, Yeh YJ, Mounzer K, Tebas P, Montaner LJ, Ho YC |
Journal of virology | 2022 |
HibeRNAtion: HIV-1 RNA Metabolism and Viral Latency.
Crespo R, Rao S, Mahmoudi T |
Frontiers in Cellular and Infection Microbiology | 2022 |
Opposing roles of CLK SR kinases in controlling HIV-1 gene expression and latency.
Dahal S, Clayton K, Been T, Fernet-Brochu R, Ocando AV, Balachandran A, Poirier M, Maldonado RK, Shkreta L, Boligan KF, Guvenc F, Rahman F, Branch D, Bell B, Chabot B, Gray-Owen SD, Parent LJ, Cochrane A |
Retrovirology | 2022 |
Cell-Associated HIV-1 Unspliced-to-Multiply-Spliced RNA Ratio at 12 Weeks of ART Predicts Immune Reconstitution on Therapy
M Scherpenisse, NA Kootstra, M Bakker, B Berkhout, AO Pasternak, TE Smithgall |
mBio | 2021 |
Shock-and-kill versus block-and-lock: Targeting the fluctuating and heterogeneous HIV-1 gene expression
YH Yeh, YC Ho |
Proceedings of the National Academy of Sciences | 2021 |
The Splice of Life: Does RNA Processing Have a Role in HIV-1 Persistence?
AO Pasternak, B Berkhout |
Viruses | 2021 |
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
SG Deeks, N Archin, P Cannon, S Collins, RB Jones, MA de Jong, O Lambotte, R Lamplough, T Ndungu, J Sugarman, CT Tiemessen, L Vandekerckhove, SR Lewin, S Deeks, S Lewin, M de Jong, Z Ndhlovu, N Chomont, Z Brumme, K Deng, L Jasenosky, R Jefferys, A Orta-Resendiz, F Mardarelli, M Nijhuis, K Bar, B Howell, A Schneider, G Turk, R Nabatanzi, J Blankson, JV Garcia, M Paiardini, J van Lunzen, C Antoniadi, FH Côrtes, S Valente, OS Søgaard, RS Diaz, M Ott, R Dunham, S Schwarze, SP Patrigeon, J Nabukenya, M Caskey, B Mothe, FS Wang, S Fidler, D SenGupta, S Dressler, M Matoga, HP Kiem, P Tebas, C Kityo, B Dropulic, M Louella, KT Das, D Persaud, A Chahroudi, K Luzuriaga, T Puthanakit, J Safrit, G Masheto, K Dubé, J Power, J Salzwedel, U Likhitwonnawut, J Taylor, OL Nuh, K Dong, EN Kankaka |
Nature Medicine | 2021 |
The Clonal Expansion Dynamics of the HIV-1 Reservoir: Mechanisms of Integration Site-Dependent Proliferation and HIV-1 Persistence
YH Yeh, K Yang, A Razmi, YC Ho |
Viruses | 2021 |
The JAK/STAT signaling pathway: from bench to clinic
X Hu, J li, M Fu, X Zhao, W Wang |
Signal Transduction and Targeted Therapy | 2021 |
A New Small-Molecule Compound, Q308, Silences Latent HIV-1 Provirus by Suppressing Tat- and FACT-Mediated Transcription
C Zhou, Y Huang, Y Li, T Liang, T Zheng, P Chen, Z Wu, F Lai, S Liu, , L Li |
Antimicrobial agents and chemotherapy | 2021 |
The Role of L-Selectin in HIV Infection
J Segura, B He, J Ireland, Z Zou, T Shen, G Roth, PD Sun |
Frontiers in microbiology | 2021 |
JAK-STAT Pathway: A Novel Target to Tackle Viral Infections
I Ezeonwumelu, E Garcia-Vidal, E Ballana |
Viruses | 2021 |
The single-cell landscape of immunological responses of CD4+ T cells in HIV versus severe acute respiratory syndrome coronavirus 2
JA Collora, R Liu, K Albrecht, YC Ho |
Current Opinion in HIV and AIDS | 2020 |